Aberrant expression of TNFR2 on tumor cells has been reported in human hematological malignancies, including Hodgkin lymphoma, cutaneous T cell lymphoma (CTCL), and multiple myeloma, as well as in breast, skin, ovarian, colon, and renal cell cancers (Arnott et al., 2004; Uhlén et al., 2005; Hamilton et al., 2011; Rauert et al., 2011; Nakayama et al., 2014; Ungewickell et al., 2015; Al-Lamki et al., 2016; Williams et al., 2016; Yang et al., 2018). The gene discussed is TNFRSF1B; the disease is neoplasm.